IGFBP-1 levels in cervicovaginal secretions before and after amniocentesis

Gynecologic and Obstetric Investigation

Volumn 67, Issue 1, 2009, Pages 9-13

  Devlieger, R ^a   Verhaeghe, J ^a   Coopmans, W ^a   Deprest, J A ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amniocentesis; Amniotic fluid; Fetal loss; Fetal membranes; Insulin like growth factor binding protein 1; Preterm prelabor rupture of membranes

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1;

ABDOMINAL PAIN; AMNIOCENTESIS; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; SECOND TRIMESTER PREGNANCY; VAGINA SECRETION;

AMNIOCENTESIS; CERVIX UTERI; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; PREGNANCY;

EID: 48649097279     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000150598     Document Type: Article

References (13)

1. Tabor A, Madsen M, Obe EB, et al: Randomised controlled trial of genetic amniocentesis in 4,606 low risk women. Lancet 1986;i:287-293.
2. Saltvedt S, Almstrom H: Fetal loss rate after second trimester amniocentesis at different gestational age. Acta Obstet Gynecol Scand 1999;78:10-14.
3. The Canadian Early and Midtrimester Amniocentesis Trial (CEMAT) Group: Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998;351:242-247.
4. Verhaeghe J, Coopmans W, van Herck E, van Schoubroeck D, Deprest JA, Witters I: IGF-I, IGF-II, IGF binding protein 1, and C-peptide in second trimester amniotic fluid are dependent on gestational age but do not predict weight at birth. Pediatr Res 1999;46:101-108.
5. Darj E, Lyrenas S: Insulin-like growth factor binding protein-1, a quick way to detect amniotic fluid. Acta Obstet Gynecol Scand 1998;77:295-297.
6. Lockwood CJ, Wein R, Chien D, Ghidini A, Alvarez M, Berkowitz RL: Fetal membrane rupture is associated with the presence of insulin-like growth factor-binding protein-1 in vaginal secretions. Am J Obstet Gynecol 1994;171:146-150.
7. Kubota T, Takeuchi H: Evaluation of insulin-like growth factor binding protein-1 as a diagnostic tool for rupture of the membranes. J Obstet Gynaecol Res 1998;24:411-417.
8. Garite TJ: Management of premature rupture of membranes. Clin Perinatol 2001;28:837-847.
9. Friedman ML, McElin TW: Diagnosis of ruptured fetal membranes. Clinical study and review of the literature. Am J Obstet Gynecol 1969;104:544-550.
10. Kilbride HW, Thibeault DW: Neonatal complications of preterm premature rupture of membranes. Pathophysiology and management. Clin Perinatol 2001;28:761-785.
11. Kishida T, Yamada H, Furuta I, Kobayashi N, Hirayama EK, Ebina Y, Cho K, Okuyama K, Fujimoto S: Persistent detection of α-fetoprotein in the vagina without overt preterm premature rupture of the membranes. Clinical and chemical characterizations. Fetal Diagn Ther 2001;16:259-264.
12. Quintero RA: New horizons in the treatment of preterm premature rupture of membranes. Clin Perinatol 2001;28:861-875.
13. Borgida AF, Mills AA, Feldman DM, Rodis JF, Egan JF: Outcome of pregnancies complicated by ruptured membranes after genetic amniocentesis. Am J Obstet Gynecol 2000;183:937-939.